53MEDIUM

PTX

PRESCIENT FPO [PTX]
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0540 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical51
Catalyst50
Sentiment50
Fundamental65
Momentum58
Risk Gate50
Get alerts when PTX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track PTX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 3.6% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
  • Adequate cash runway (5 quarters)
  • 4C filed 2026-01-29
  • Moderate P/S ratio (13.3x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (18% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Positive long-term momentum — up 48% over the past year
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-7%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-208%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.83%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about PTX
"What's driving PTX's score?" "How does PTX compare to peers?" "Key risks for PTX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Updated Securities Trading Policy
NONE Appendix 4D and Half Year Financial Report
MEDIUM December 2025 Quarterly Update and Appendix 4C

Recent ASX Announcements

2026-02-24 Updated Securities Trading Policy
2026-02-24 Appendix 4D and Half Year Financial Report PRICE SENSITIVE
2026-01-29 December 2025 Quarterly Update and Appendix 4C PRICE SENSITIVE

Key Metrics

$56.8M
Market Cap
887K
Avg Volume
0.5x
Vol Ratio
$0.04 — $0.12
52-Week Range
N/A
Short Interest
5 qtrs
Cash Runway
-54.3%
ROE
-207.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 88%
LLeader vs LaggardlaggardRS: -8
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #16 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:PTX vs ATXPTX vs PNVPTX vs IMM
Scout Pro — Deeper Analysis for PTX
Try Pro free for 30 days
Share this analysis

Track PTX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required